Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Type I Diabetes II: Pathophysiology

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...

Type I Diabetes I: Introduction

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...

Diabetes Mellitus: Overview and Type I Subtype

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...

Type II Diabetes II: Pathophysiology

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.

Type I Diabetes III: Clinical Manifestations

Type I Diabetes III: Clinical Manifestations

Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...

Type II Diabetes I: Introduction

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Cell Therapy: A New Technology for Cerebral Circulation Restoration after Ischemia/Reperfusion.

Acta naturae·2023

Same author

Contribution of Hydrogen Sulfide to Dilation of Rat Cerebral Arteries after Ischemia/Reperfusion Injury.

Bulletin of experimental biology and medicine·2020

Same author

Cerebral Blood Flow in SHR Rats after Transplantation of Mesenchymal Stem Cells.

Bulletin of experimental biology and medicine·2019

Same author

EFFICACY OF MESENCHYMAL STEM CELLS USED FOR THE IMPROVEMENT CEREBRAL MICROCIRCULATION IN SPONTANEOUSLY HYPERTENSIVE RATS.

Tsitologiia·2018

Same author

[Functional cumulation of influence of vascular peptide bioregulator on microcirculation in the brain cortex of spontaneously hypertensive rats.]

Advances in gerontology = Uspekhi gerontologii·2018

Same author

[The effect of intracerebral transplantation of mesenchymal stem cells on orientation and exploratory behavior of aged animals].

Advances in gerontology = Uspekhi gerontologii·2017

Search research articles

Related Experiment Video

Updated: Jun 16, 2026

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

[Cell therapy for type I diabete].

|February 10, 2010

Summary

Cell therapy offers a promising treatment for type I diabetes mellitus using various cell types. While current methods can improve patient status, complete recovery remains an ongoing challenge in regenerative medicine.

Area of Science:

Regenerative Medicine
Immunology
Endocrinology

Context:

Type I diabetes mellitus (T1DM) is an autoimmune disease characterized by pancreatic beta-cell destruction.
Current T1DM management relies on lifelong insulin replacement therapy, which has limitations.
Cell therapy presents a novel therapeutic strategy for T1DM by aiming to restore insulin production.

Purpose:

To review the current landscape of cell therapy approaches for type I diabetes mellitus.
To evaluate the efficacy and limitations of various cell types used in T1DM treatment.
To identify future directions for achieving full recovery in T1DM patients through cell-based interventions.

Summary:

Various cell types, including allogeneic and xenogeneic islet cells, bone marrow cells, hematopoietic stem cells, mesenchymal stem cells, and cord blood stem cells, are being investigated for T1DM treatment.

More Related Videos

Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice

Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice

Published on: November 18, 2022

Related Experiment Videos

Last Updated: Jun 16, 2026

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice

Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice

Published on: November 18, 2022

These cell types have demonstrated the potential to partially correct the metabolic status of T1DM patients.

Despite advancements, complete and sustained remission of type I diabetes mellitus following cell therapy has not yet been consistently achieved.

Impact:

Cell therapy holds significant promise for improving the quality of life for individuals with type I diabetes.
Further research is crucial to overcome existing challenges and achieve full functional recovery.
This field has the potential to revolutionize T1DM treatment paradigms, moving beyond insulin dependency.